Bölge seçiniz
Gönder

Haber akışımıza abone olun

Abone ol

Bir soru?

22.04.2024
Resolutions at Getinge’s Annual General Meeting 22 April 2024

Getinge AB (publ)’s Annual General Meeting (“AGM”) was held on 22 April 2024 in Kongresshallen, Hotel Tylösand, Halmstad, Sweden. At the AGM, the following was resolved.

22.04.2024
Getinge Interim Report January-March 2024: Higher sales, strong cash flow and new products creating more customer value

“Net sales increased by 5.2% in the first quarter, of which organic net sales was unchanged despite challenging comparative figures,” says Mattias Perjos, President & CEO at Getinge. “We have a strong free cash flow and a solid financial position that enables investments in profitable growth.”

18.04.2024
NAVA – a gamechanger for neonatal care in Slovakia

When using Getinge’s patented Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) for the first time in 2021, it soon became clear to the neonatal team in the F.D. Roosevelt University Hospital in Banska Bystrica, Slovakia, that the solution would become a gamechanger for their treatment of premature babies.

11.04.2024
Getinge receives EU MDR approval of Advanta V12 covered stent system with use for patients with renal artery stenosis and/or aortoiliac occlusive disease

Getinge announces the EU MDR certification of its Advanta V12 covered stent system, highlighting its use for patients with aortoiliac occlusive disease, including lesions at the aortic bifurcation. This approval affirms the system's compliance with European Union medical device regulations and aligns its application, reflecting Getinge's commitment to quality and patient safety.

8.04.2024
Getinge invites fund managers, analysts, and media to Q1 Report 2024 conference call

Getinge will issue its Q1 Report 2024 on April 22, 2024, at 12:00 p.m. CEST, followed by a conference call at 13:00-14.00 p.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.

28.03.2024
Getinge extends the bioreactor portfolio with larger single-use systems

Getinge is extending its bioreactor offering by introducing the Single-Use Production Reactor (SUPR) system, which initially is available in 50-liter and 250-liter sizes. Based on the same proven platform as Getinge’s smaller bioreactors, the SUPR system helps operators to bring life-saving medicines faster to market, aiming to improve people’s quality of life.

Basın iletişim

Lars Mattsson

Interim EVP Brand & Communication
Phone: +46 10 335 0043

Caroline Örmgård

Head of Public & Media Relations
Tel: +46 10 335 0041

Katarzyna Sypuła

Head of Marketing Communications CEE/MEA
Tel: +48 661 705 706

Newsroom2

Bizimle çevrimiçi iletişime geçmeyi mi tercih ediyorsunuz?

Uygun formu doldurmak için aşağıya tıklayın. Yakında sizinle iletişime geçeceğiz!

Mı arıyorsun

Getinge Hybrid OR

Resim Galerisi

Basın makalesi amacıyla kullanıma sunulan çeşitli resim formatı

Man and woman looking a something together

Hakkımızda

Bir bakışta Getinge hakkında bilmeniz gereken her şey

Cardiosave

Acil Tıbbi Cihaz Düzeltmesi

CARDIOSAVE intra-aortik balon pompası (IABP) için Gönüllü Acil Tıbbi Cihaz Saha Düzeltmesi

Newsroom

Hiçbir şeyi kaçırma

Simgelere tıklayın ve bizi takip edin!